tirzepatide research A 3-year study of in participants with obesity and prediabetes showed substantial and sustained weight reduction and decreased risk of progression to diabetes with tirzepatide, as compared with placebo. Full SURMOUNT-1 Read now: The SURPASS-EARLY trial

Higher GLP-1 receptor occupancy at 1 mg produces greater reductions in HbA1c and body weight compared to 0.5 mg, with a modest increase in GI adverse effects during the period after dose escalation

In diabetes care, endocrinologists bring deep knowledge of insulin dynamics, complication management, and complex pharmacotherapy

Earlier results from the same international research team showed that semaglutide lowered the risk of heart attacks, strokes, and other major cardiac events by 20%

Running multiple peptides simultaneously represents a significant ongoing expense

Essential Nutrients to Preserve Hair Health During GLP-1 Therapy Protein deficiency is the primary driver of GLP-1-related hair loss

Avid sun exposure and tanning before treatment